Pfizer's Diversity Program Faces Legal Heat, Advocacy Group Revives Discrimination Case
Portfolio Pulse from Vandana Singh
Advocacy group Do No Harm has appealed to the 2nd U.S. Circuit Court to revive its lawsuit against Pfizer Inc, alleging that Pfizer's diversity fellowship program discriminates against white and Asian-American applicants. Pfizer defended its position, stating that the program has been modified to accept applicants of any race from 2023, provided they meet specific non-race-based criteria. The lawsuit was filed in September 2022, and the court's decision is pending.
October 04, 2023 | 2:26 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Pfizer is facing a revived lawsuit from advocacy group Do No Harm, alleging discrimination in its diversity program. The company has defended its position, stating that the program will accept applicants of any race from 2023.
The lawsuit, if successful, could potentially harm Pfizer's reputation and investor confidence, leading to a negative impact on its stock price. However, the company's defense that the program has been modified to be more inclusive could mitigate some of this impact.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100